Porownywarka
Kisspeptin vs Gonadorelin side-by-side
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Porownywarka
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Wybrane (2/4)
Udostępnij porównanie peptydów
| Wlasciwosc | Kisspeptin | Gonadorelin |
|---|---|---|
| Kategoria | Hormonalne | Hormonalne |
| Znany tez jako | Kisspeptin-10, Kisspeptin-54, Metastin | GnRH, LHRH, Factrel |
| Zatwierdzony przez FDA | Nie | Tak |
| Status kliniczny | Investigational - Clinical trials ongoing Nie dotyczy | Previously FDA approved as Factrel for diagnostic use; that brand is discontinued, no FDA-approved gonadorelin product is currently marketed in the US, and the source reports availability only as 503A-compounded.
|
| Czego oczekiwac | Fertility, testosterone, reproductive hormone optimization | Hormone stimulation, fertility, TRT support |
| Jak dziala | Kisspeptin is described as acting through KISS1R/GPR54 receptors on GnRH neurons in the hypothalamus. The reported intracellular pathway includes phospholipase C activation with IP3 and DAG second messengers, followed by increased GnRH release. GnRH then drives pituitary gonadotropin output, including LH and FSH, linking kisspeptin signaling to ovarian and testicular hormone regulation. The source also notes genetic evidence: inactivating KISS1 or KISS1R mutations are associated with pubertal failure and infertility, while activating mutations are associated with precocious puberty. | Gonadorelin is described as a synthetic GnRH peptide that engages GnRH receptors on gonadotroph cells in the anterior pituitary. The source reports signaling through phospholipase C with calcium and protein kinase C involvement, leading to LH and FSH production and release. Those gonadotropins then influence ovarian or testicular function, including sex-steroid production and gamete development. The source emphasizes pattern of exposure: pulsatile delivery, similar to endogenous GnRH rhythms of about 60 to 120 minutes, supports stimulation, whereas continuous exposure can desensitize and downregulate the receptor and reduce LH and FSH output. |
| Typowe dawkowanie | 100-200 mcg subcutaneously once daily · Once daily or every other day | 100-500 mcg 2-3x weekly · 2-3x weekly · IV, subcutaneous, or pulsatile pump |
| Dawkowanie z badań | Kisspeptin-10: 1-10 nmol/kg IV · Variable by protocol · IV (research), subcutaneous (investigational) | 100 mcg IV/SC for diagnostic testing · Single dose (diagnostic) or ongoing (therapeutic) · IV, subcutaneous, or pulsatile pump |
| Typowy czas trwania | Variable by protocol | Single dose (diagnostic) or ongoing (therapeutic) |
| Podanie | IV (research), subcutaneous (investigational) | IV, subcutaneous, or pulsatile pump |
| Timing | Morning or as directed With or without food | Morning or as clinically directed With or without food |
| Poziom dowodów | Badania kliniczne | Zatwierdzone przez FDA |
| Mozliwe skutki uboczne |
+3 więcej
|
+4 więcej
|
| Podsumowanie researchu | The supplied evidence reports several human research contexts. In women with hypothalamic amenorrhea, subcutaneous kisspeptin-54 was reported to raise LH about 10-fold and FSH about 2.5-fold into the normal range, and infusion protocols were reported to restore LH pulse frequency. In an IVF setting, kisspeptin-54 was used to trigger oocyte maturation, with a live term birth reported, and the source says it has been explored as a potentially gentler trigger with possible ovarian hyperstimulation risk reduction. In hypogonadal men, kisspeptin-10 infusion reportedly increased LH roughly 5-fold and moved testosterone into the normal range. The same source cautions that these data mainly come from small academic studies and specialist infusion protocols, not large multi-center phase 3 trials, and that short-term hormone changes do not establish long-term safety. | The source frames gonadorelin as an established GnRH molecule rather than an experimental novelty. Diagnostic GnRH stimulation testing is described as established, and pulsatile pump administration is reported in hypogonadotropic hypogonadism, delayed puberty, and fertility induction. Because the peptide is short-lived, the source notes that historical clinical use depended on pumps or frequent administration, while longer-acting GnRH agonists later displaced some uses. The source also describes off-label TRT-adjunct use as common in some clinic and online settings, but supported mainly by mechanism, small-scale experience, or anecdote rather than large randomized comparisons showing superiority over HCG. |
| Referencje | ||
| Pełny profil | Zobacz szczegóły | Zobacz szczegóły |
Zapisz to porównanie
Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.
Zapisz porównanie - darmowe kontoTrackuj swoja ścieżkę peptydówa
Zamien research w prywatny log protokołu, gdy będziesz gotowy.
Trackuj ścieżkę peptydówaWyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.